0000950170-24-032213.txt : 20240315
0000950170-24-032213.hdr.sgml : 20240315
20240315161909
ACCESSION NUMBER: 0000950170-24-032213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAPADOPOULOS STELIOS
CENTRAL INDEX KEY: 0001202098
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35670
FILM NUMBER: 24755044
MAIL ADDRESS:
STREET 1: 3 SOMERSET DRIVE SOUTH
CITY: GREAT NECK
STATE: NY
ZIP: 11020
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Regulus Therapeutics Inc.
CENTRAL INDEX KEY: 0001505512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 264738379
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4224 CAMPUS POINT COURT
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-202-6300
MAIL ADDRESS:
STREET 1: 4224 CAMPUS POINT COURT
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-03-14
0001505512
Regulus Therapeutics Inc.
RGLS
0001202098
PAPADOPOULOS STELIOS
C/O REGULUS THERAPEUTICS INC.
4224 CAMPUS POINT COURT #210
SAN DIEGO
CA
92121
true
false
false
false
false
Common Stock
2024-03-14
4
A
false
250000
1.60
A
978388
D
The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated March 11, 2024, with a closing date of March 14, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof.
Christopher Aker, Attorney in Fact
2024-03-15